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To successfully establish infection, flaviviruses have
to overcome the antiviral state induced by type I
interferon (IFN-I). The nonstructural NS5 proteins of
several flaviviruses antagonize IFN-I signaling. Here
we show that yellow fever virus (YFV) inhibits IFN-I
signaling through a unique mechanism that involves
binding of YFV NS5 to the IFN-activated transcription
factor STAT2 only in cells that have been stimulated
with IFN-I. This NS5-STAT2 interaction requires
IFN-I-induced tyrosine phosphorylation of STAT1
and the K63-linked polyubiquitination at a lysine in
the N-terminal region of YFV NS5. We identified
TRIM23 as the E3 ligase that interacts with and poly-
ubiquitinates YFV NS5 to promote its binding to
STAT2 and trigger IFN-I signaling inhibition. Our re-
sults demonstrate the importance of YFV NS5 in
overcoming the antiviral action of IFN-I and offer a
unique example of a viral protein that is activated
by the same host pathway that it inhibits.
INTRODUCTION
There is an urgent need for therapeutics against flaviviruses.
There were 5,674 cases of West Nile virus (WNV) infection in
the United States in 2012 resulting in 286 deaths (Hadler et al.,
2014), yet this number pales in comparison to the more than
200,000 cases of hemorrhagic disease and death caused annu-
ally by dengue virus (DENV). Even in the case of yellow fever virus
(YFV), for which there is a highly efficacious vaccine, there are
200,000 reported cases annually with at least 30,000 deaths.
Despite the success of the live-attenuated YFV-17D vaccine, oc-
currences of vaccine-associated viscerotropic and neurotropic
disease have brought its safety into question (Barrett et al.,
2007; Biscayart et al., 2014; Breugelmans et al., 2013; Monath
et al., 2005).314 Cell Host & Microbe 16, 314–327, September 10, 2014 ª2014 ElThe flavivirus genome is a single-stranded, positive-sense
RNA that encodes a polyprotein that is cleaved co- and post-
translationally by viral and host proteases generating three
structural proteins, C (core), prM-M (membrane protein and its
precursor), and E (envelope) and seven nonstructural (NS)
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The
structural proteins form the virion particle, whereas the NS pro-
teins have roles in viral RNA replication, polyprotein processing,
and host immune evasion (Aguirre et al., 2012; Chambers et al.,
1990a, 1990b; Diamond, 2009; Rice et al., 1985). NS5 is
the largest and most conserved of the flavivirus proteins. Its
C terminus encodes the viral RNA-dependent RNA polymerase
(Lindenbach and Rice, 2003), whereas its N terminus contains
an S-adenosyl-methyltransferase (SAM) domain and is involved
in methylation of the 50 RNA cap structure of the viral RNA (Issur
et al., 2009; Zhou et al., 2007a). The middle portion contains at
least two nuclear localization sequences whose roles in viral
replication are still uncharacterized (Brooks et al., 2002).
Type I interferon (IFN-I or IFN-a/b) induces an antiviral state in
cells to curb viral replication and dissemination. Binding of IFN-I
to its receptor activates JAK1 and TYK2, which phosphorylate
and activate STAT1 and STAT2, resulting in the formation of
IFN-stimulated gene factor 3 (ISGF3), a transcription factor com-
plex comprised of IRF9 and phosphorylated STAT1 and STAT2.
ISGF3 translocates to the nucleus where it binds to IFN-I-stimu-
lated response elements (ISREs) and promotes the transcription
of IFN-stimulated genes (ISGs), which encode proteins with anti-
viral activities (Der et al., 1998; Horvath et al., 1996; Schoggins
et al., 2011).
Several flaviviruses including DENV, WNV, Japanese enceph-
alitis virus (JEV), Langat virus (LGTV), and tick-borne encephalitis
virus (TBEV) encode IFN-I antagonists (Ashour et al., 2009;
Best et al., 2005; Jones et al., 2005; Laurent-Rolle et al., 2010;
Lin et al., 2006;Werme et al., 2008;Mazzon et al., 2009;Morrison
et al., 2013). Our present work describes a mechanism of virus-
mediated IFN-I signaling inhibition that is unique among all vi-
ruses described thus far. We show that IFN-I induces binding of
YFV NS5 to STAT2, preventing its transcriptional activity by (1)
increasing K63-linked polyubiquitination at residue K6 of YFV
NS5, thereby promoting the capacity of YFV NS5 to inhibit IFN-Isevier Inc.
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(Tyr) phosphorylation, which is required for NS5/STAT2 binding.
RESULTS
YFV Antagonizes IFN-I-Stimulated Gene Expression
YFV and DENV share a similar host tropism, are spread by the
same vector species, and can both cause hemorrhagic disease.
Because DENVwas known to antagonize IFN-I signaling (Ashour
et al., 2009; Jones et al., 2005), we examined whether YFV
(YFV-17D) would also have this ability. YFV infection caused a
5-fold reduction in IFN-I-mediated ISRE promoter activation
(Figure 1A), but did not reduce IFN-II (IFN-g)-stimulated GAS
activity (Figure 1B). In addition, IFN-I but not IFN-II signaling
was reduced in YFV-infected Vero cells as demonstrated with
an NDV-GFP bioassay (Park et al., 2003; Figure 1C).
To identify the step of the IFN-I signaling pathway that is tar-
geted by YFV, the expression, phosphorylation, and nuclear
translocation of STAT1 and STAT2 were examined in YFV-in-
fected cells. Immunofluorescence analysis (Figures 1D and 1E)
and western blots (Figure 1F) revealed that STAT1 and STAT2
levels were not reduced by YFV infection. If anything, STAT2
levels were increased (Figure 1F). Furthermore, IFN-I-induced
phosphorylation and nuclear translocation of the STATs were
unaffected (Figures 1D–1F), suggesting that YFV interference is
downstream of tyrosine phosphorylation and nuclear transloca-
tion of the STATs.
We next examined whether YFV inhibits IFN-I signaling at the
level of DNA binding of ISGF3. For this purpose, electrophoretic
mobility shift assays were carried out with lysates from IFN-I-
treated YFV-infected Vero cells. ISGF3 failed to bind to the
ISRE derived from the Oas1b promoter in extracts from IFN-I-
treated, YFV-infected, or DENV-2-infected Vero cells (Figure 1G).
Antibodies against IRF7 did not disrupt DNA-protein complex
formation, whereas antibodies against STAT2 did, confirming
the identity of the complex as ISGF3 (Figure 1G).
YFV NS5 Inhibits IFN-I Signaling
Because the NS5 proteins of LGTV, JEV, DENV, and WNV had
previously been identified as IFN antagonists (Ashour et al.,
2009; Best et al., 2005; Laurent-Rolle et al., 2010; Lin et al.,
2006; Mazzon et al., 2009; Morrison et al., 2013), we reasoned
that YFV NS5 might also be an IFN-I signaling antagonist.
Expression of YFV NS5 reduced IFN-I mediated ISRE promoter
activation comparable to the positive controls, Nipah virus
(NiV) V, DENV-2 NS5, and WNV NS5 (Figure 2A). Expression of
DENV-2 Core did not inhibit CAT activity (Figure 2A).
The NS5 proteins of the virulent YFV-Asibi strain and the YFV-
17D vaccine strain differ by three amino acids (aa; dos Santos
et al., 1995; Hahn et al., 1987). We examined the ability of both
YFV NS5 proteins to inhibit IFN-I signaling by investigating their
impact on ISG54 promoter activation after stimulation with exog-
enous IFN-b. Both proteins behaved similarly in the ISG54 re-
porter assay (Figure 2B).
YFV NS5 Interacts with STAT2 in the Presence of IFN-I
and IFN-III
YFV’s antagonism of IFN-I but not IFN-II signaling (Figure 1) sug-
gested that the virus was targeting a factor such as TYK2,Cell Host & MSTAT2, or IRF9 that is specific to the IFN-I pathway. Because
DENV-2 NS5 targets STAT2, and DENV and YFV NS5 are
60% identical at the aa level, we examined whether YFV
NS5, like DENV-2 NS5, would interact with STAT2 (Ashour
et al., 2009). Immunoprecipitation experiments in 293T cells
expressing YFV-17D NS5, YFV-Asibi NS5, empty plasmid, or
DENV-2 NS5 revealed STAT2 coprecipitation with DENV-2
NS5 but not YFV NS5 (Figure 2C). The DENV NS5 expression
construct used in this study does not enable proteolytic process-
ing of its N terminus; therefore, only STAT2 binding, and not
degradation, is observed (Ashour et al., 2009). When immuno-
precipitation experiments were performed in cells stimulated
with IFN-I, both YFV-17D NS5 and YFV-Asibi NS5 associated
with STAT2 (Figure 2C). Similar results were observed in cells
stimulated with IFN-III (IFN-l), but not IFN-II (Figure 2D). Like
IFN-I, IFN-III signals through JAK1/TYK2 and ISGF3, leading to
an IFN-I-like transcriptional profile (Ank et al., 2006; Zhou et al.,
2007b). Because both the 17D and Asibi NS5 proteins behaved
similarly in the reporter and binding assays (Figures 2B and 2C),
we used YFV-Asibi NS5 for the remainder of the study.
IFN-I-Induced Modification of STAT2 Is Not Required for
STAT2 Interaction with YFV NS5
YFV NS5 localizes to both the cytoplasm and nucleus but is pre-
dominantly nuclear (Figure 1F and Figure S1A available online).
Because YFV NS5 binds STAT2 in cells treated with IFN-I,
we examined whether IFN-I-mediated nuclear translocation of
STAT2 was required for YFV NS5 to interact with STAT2. Cell
fractionation assays revealed that YFV NS5 bound STAT2 in
the cytoplasmand the nucleus of IFN-I-treated cells (Figure S1A).
Thus IFN-I-induced nuclear translocation of STAT2 is not
required for binding to YFV NS5.
We examined whether IFN-I-mediated modification of STAT2
was required for YFVNS5 to interact with STAT2. Coimmunopre-
cipitation assays were performed with lysates from U6A cells,
which lack endogenous STAT2 (Leung et al., 1995), transfected
with YFV NS5 along with wild-type STAT2 or a STAT2 mutant
that was incapable of IFN-induced tyrosine phosphorylation
(STAT2 Y690F; Leung et al., 1995; Qureshi et al., 1996). YFV
NS5 associated with both wild-type STAT2 and mutant STAT2
in IFN-I-treated cells, indicating that IFN-I-mediated STAT2
tyrosine phosphorylation is not required for this interaction (Fig-
ure S1B). We also confirmed that STAT1 phosphorylation re-
mained intact in U6A cells upon IFN stimulation (Figure S1C).
Confocal immunofluorescence showed YFV NS5 colocalization
with wild-type and mutant STAT2 only after IFN-I treatment
(Figure 3A).
We next determined if IFN-I was inducing modifications of
YFV NS5 and/or cellular proteins other than STAT2 to promote
YFV NS5-STAT2 interaction. U6A cells were transfected with a
construct expressing HA-tagged YFV NS5. After 24 hr, the
cells were either mock stimulated or treated with IFN-I. U6A
cell lysates were subjected to immunoprecipitation using anti-
HA beads to precipitate NS5. The beads were washed then incu-
bated with lysates from mock-treated or IFN-I-treated 2fTGH
cells, the STAT2-proficient U6A parental line. YFV NS5 inter-
acted with STAT2 only when YFV NS5 had been precipitated
from IFN-I-treated U6A cells, regardless of whether 2fTGH cells
were IFN-I-treated or mock-treated (Figure 3B). In contrast,icrobe 16, 314–327, September 10, 2014 ª2014 Elsevier Inc. 315
Figure 1. YFV Inhibits IFN-I but Not IFN-II Signaling
(A and B) 293T cells were transfected with (A) an IFN-I-inducible firefly-luciferase (f-luc) reporter plasmid (ISRE-luciferase) or (B) an IFN-II-inducible f-luc reporter
(GAS-luciferase) along with a constitutively expressing Renilla luciferase (R-Luc) gene plasmid. Cells were infected with DENV-2 or YFV-17D viruses (moi = 5) for
24 hr and treated with IFN-b or IFN-g (1,000 U/ml) for 16 hr prior to assaying for luciferase activity. Fold induction of f-luc was normalized to R-luc. The bars
represent the mean fold induction of three independent experiments compared to untreated, mock-infected controls.
(C) Vero cells were mock infected or infected with YFV-17D virus (moi = 5). At 24 hr postinfection (hpi), cells were mock treated or treated with the indicated
amounts of IFN-b or IFN-g for 16 hr then infected with NDV-GFP. NDV-GFP replication was monitored by fluorescence microscopy at 14 hpi.
(D and E) Confocal microscopy images showing subcellular localization of the indicated protein in mock-infected or YFV-17D-infected (moi = 1) Vero cells before
or after treatment with IFN-b for 30 min.
(F) Intracellular fractionation of mock infected or YFV-17D-infected HeLa cells (moi = 10). The proteins in the cytoplasmic and nuclear fractions were detected by
western blotting with the indicated antibodies.
(G) Vero cells were mock-infected or infected with DENV-2 or YFV-17D viruses for 24 hr (moi = 10), then either mock-stimulated or stimulated with IFN-b for 8 hr.
Cell extracts were analyzed by electrophoretic mobility shift assays with ISRE elements derived from the Oas1b gene. Statistical analyses were conducted using
the unpaired t test in Prism 4 for Macintosh (GraphPad Software). ns, no significance, where p > 0.05; ***p < 0.0001.
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ing efficiencies of YFV NS5 and DENV NS5 to STAT2 is likely due
to (1) the complexes are made in different lysates decreasing316 Cell Host & Microbe 16, 314–327, September 10, 2014 ª2014 Elcomplex formation; (2) DENV NS5 may interact directly with
STAT2, whereas YFV NS5 interaction may be indirect; and (3)
YFV NS5 may require both STAT1/2 to be complexed beforesevier Inc.
Figure 2. YFV NS5 Inhibits IFN-I Signaling and Interacts with STAT2 in IFN-I- and IFN-III-Treated Cells
(A) 293T cells were cotransfected with a plasmid encoding an ISRE-54-CAT-GFP reporter and with a constitutively expressing firefly-luciferase (f-luc) plasmid
plus an empty vector or viral protein encoding plasmids. At 24 hr posttransfection, cells were treated with IFN-b for 16 hr prior to assaying for CAT activity.
Induction of CAT activity was normalized to f-luc activity. Lower: Western blot showing the relative expression of each transfected viral protein.
(B) 293T cells were cotransfected with an IFN-I-inducible f-luc reporter plasmid (pISRE-luc) along with a constitutively expressing Renilla luciferase (R-luc) gene
plasmid and empty vector or YFV-17D and YFV-Asibi NS5 expression plasmids. At 24 hr posttransfection, cells were treated with IFN-b for 16 hr prior to assaying
for luciferase activities. Fold induction of f-luc was normalized to R-luc. The bars represent the mean fold induction of three independent experiments compared
to untreated empty vector controls. Lower: Western blot (WB) showing the relative expression of each transfected viral protein.
(C) 293T cells were transfected with the indicated NS5 expression plasmids. At 24 hr, cells were mock stimulated or stimulated with IFN-b for 45 min. Cells were
lysed and immunoprecipitation was performed followed by WB with the indicated antibodies.
(D) Same experiment as in (C) with cells mock-stimulated or stimulated with 1,000 U/ml of IFN-b, IFN-g, or IFN-l for 45 min prior to lysis. WCE, whole cell extract;
CAT, chloramphenicol acetyl transferase.
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these data suggest that IFN-I signaling modifies YFV NS5 and/
or a cellular interactor promoting NS5 binding to STAT2.
The N Terminus of YFV NS5 Is Required for IFN-I
Signaling Antagonism
To map the domain of YFV NS5 required for IFN-I signaling inhi-
bition, N-terminally truncated NS5 mutants were tested for
STAT2 binding. Removal of the first ten aa resulted in a loss of
YFV NS5-STAT2 association (Figure S2). Chimeric proteins
were constructed to ensure that mutant YFV NS5was expressed
in the context of a full-length NS5 molecule then tested for their
ability to bind STAT2 and inhibit IFN-I signaling. Substitution of
the first ten aa of YFV NS5 with the first ten or 11 residues of
WNV, DENV-2, and Modoc virus (MODV; Figure 4A) revealed
that only WNV-YFV NS5 associated with STAT2 and inhibited
IFN-I signaling (Figures 4B and 4C). Next we examined whether
the first ten aa of YFV NS5 were sufficient for binding STAT2 by
substituting the first ten aa of WNV NS5 for those of YFV NS5Cell Host & M(YFV-WNV NS5; Figure S3). YFV-WNV NS5 did not bind
STAT2, indicating that the first ten aa of YFVNS5were necessary
but insufficient for this association.
ALysine Residuewithin the First Ten Amino acids of YFV
NS5 Is Required for Its IFN-I Antagonist Function
A comparison of the first ten aa of the flaviviral NS5 proteins re-
vealed a lysine (K) at position 6 of YFV NS5 and a K at position 4
(K4) of WNV NS5 that could account for the YFV NS5/STAT2
interaction. Importantly, the ten aa of DENV and MODV did not
have K residues. Mutation of K6 to an arginine, YFV NS5 K6R
(Figure 4A), abolished the ability of YFV NS5 to associate with
STAT2 after IFN-I stimulation (Figure 4D) and inhibit the ISRE
promoter (Figure 4E). Substitution of the proline at position 7 of
MODV-YFV NS5 with a K (MODV-YFV NS5 P7K; Figure 4A)
rescued MODV-YFV NS5’s capacity to bind STAT2 and inhibit
ISRE promoter activity (Figures 4D and 4E).
The dissimilarity of the N-termini of YFV and MODV and the
ability of MODV-YFV NS5 P7K to bind STAT2 suggested thaticrobe 16, 314–327, September 10, 2014 ª2014 Elsevier Inc. 317
Figure 3. Neither IFN-I-Mediated Phosphorylation nor Nuclear Translocation of STAT2 Are Required for STAT2 Interaction with YFV NS5
(A) Confocal microscopy images showing subcellular localization of the indicated proteins in Vero cells before or after treatment with IFN-b for 45 min.
(B) U6A cells were transfected with the indicated plasmids. At 24 hr, cells were mock stimulated or stimulated with IFN-b for 45 min. Cells were lysed and
immunoprecipitation was performed against the HA epitope for 2 hr using anti-HA beads. The beads were then washed three times with lysis buffer. 2fTGH cells
were mock stimulated or stimulated with IFN-b, then lysed and added to the NS5-bound anti-HA beads for 2 additional hours. The protein was eluted from
washed beads then used for western blot.
Cell Host & Microbe
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Figure 4. A Single Lysine Residue at Position 6 of YFV NS5 Is Critical for IFN-I Antagonist Function
(A) Diagram of the YFV NS5 expression constructs used in Figure 4.
(B and D) 293T cells were transfected with the indicated plasmids. At 24 hr posttransfection, cells were mock stimulated or stimulated with IFN-b for 45 min. Cells
were lysed and immunoprecipitation was performed followed by western blot analysis with the indicated antibodies.
(C and E) 293T cells were cotransfected with an IFN-b-inducible firefly-luciferase (f-luc) reporter plasmid (pISRE-luc) along with a constitutively expressing R-luc
plasmid plus empty vector or plasmids encoding the indicated viral proteins. At 24 hr, cells were treated with IFN-b for 16 hr prior to assaying for luciferase
activities. Fold induction of f-luc activity was normalized to R-luc activity. The bars represent themean fold induction of three independent experiments compared
to the untreated, empty vector controls.
(F) Vero cells were infected with either YFV-17DWT or YFV-17D K6R at an moi of 10. At 8 hpi, the cells were either mock-treated or treated with 100 U/ml IFN-b.
Virus was harvested at the indicated time points and viral titers were quantified by plaque assay on BHK-21 cells. Each point on the graph represents themean of
four independent experiments. Statistical analyses were conducted using the unpaired t test in Prism 4 (GraphPad Software). ns, no significance, where p > 0.05;
***p < 0.0001; **p < 0.001.
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Figure 5. K63-Linked Ubiquitination Is Required for Binding of YFV NS5 to STAT2
(A) 293T cells were transfected with various NS5 mutants. At 24 hr posttransfection, cells were mock stimulated or stimulated with IFN-b for 45 min. Cells were
lysed and immunoprecipitation was performed followed by western blot analysis (WB) with the indicated antibodies.
(B) Same as (A), but with more stringent conditions.
(C) U6A cells were transfected with HA-tagged YFV NS5. At 24 hr, cells were mock stimulated or stimulated with IFN-b. Cells were lysed and immunoprecipitation
was performed against the HA epitope for 2 hr using HA beads. Beads were washed three times with lysis buffer followed by incubation with reaction buffer or
OTU. 2fTGH cells weremock stimulated or stimulated with 1,000 U/ml IFN- b. Cells were lysed andwere added to the HA beads for 2 hr. Beadswere thenwashed
followed by WB with the indicated antibodies.
(D) Diagram of the YFV NS5 constructs used in (E) and (F).
(E) Same experiment as in (A) with the indicated constructs.
(F) 293T cells were cotransfected with an IFN-a/b-inducible firefly-luciferase (f-luc) reporter plasmid (pISRE-luc) along with a constitutively expressing Renilla
luciferase (R-luc) gene plasmid plus empty vector or plasmids encoding the indicated viral proteins. At 24 hr, cells were treated with IFN-b for 16 hr prior to
(legend continued on next page)
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lysine. We generated YFV NS5 constructs missing the first five
aa (D5-YFV NS5) or the first ten aa except K (K-D10-YFV NS5;
Figure 4A). Coimmunoprecipitation assays (Figure 4D) and re-
porter assays (Figure 4E) showed that these proteins were able
to bind STAT2 and inhibit IFN signaling, emphasizing the require-
ment of the lysine residue in the N-terminal region of NS5. An
alignment of the YFV genome sequences in the virus pathogen
resource revealed that K6 of YFV NS5 is conserved across
strains (Figure S4A).
Introduction of the K6Rmutation into YFV-17D (YFV-17D K6R)
did not affect viral replication as compared to wild-type virus
(YFV-17DWT; Figure 4F). However, IFN-I treatment at 8 hr post-
infection, decreased YFV-17D K6R titers by one log relative
to YFV-17D WT (Figure 4F). In addition, the upregulation of
ISGs in YFV-17D K6R-infected cells was comparable to that in
IFN-treated mock-infected cells (Figures S4B and S4C). These
results indicate that K6 of YFV NS5 is critical for NS5-STAT2
interaction and inhibition of IFN-I-mediated antiviral activity.IFN-I Enhances K63-Linked Polyubiquitination of YFV
NS5 and Promotes YFV NS5-STAT2 Interaction
Lysine residues are critical for the posttranslational modifica-
tion of proteins through conjugation to acetyl (acetylation),
ubiquitin (ubiquitination), small ubiquitin-like modifier (SUMO;
SUMOylation), Nedd8 (NEDDylation), and interferon-stimulated
gene-15 (ISG15; ISGylation; Chen and Gerlier, 2006; Hemelaar
et al., 2004). Thus, we investigated whether the K6 residue
of YFV NS5 was posttranslationally modified and if that modif-
ication was required for STAT2 binding. The 293T cells were
cotransfected with empty vector, MODV-YFV NS5, YFV NS5,
TRIM25, or TRIM19 along with UB, ISG15, or SUMO (Figure S5).
TRIM25 serves as a positive control for ubiquitination and ISGy-
lation (Gack et al., 2007), whereas TRIM19 serves as a positive
control for SUMOylation (El Bougrini et al., 2011). Coimmunopre-
cipitation assays demonstrated that YFVNS5was possibly ubiq-
uitinated, but not ISGylated or SUMOylated (Figure S5). An
increase in ubiquitination of YFV NS5 was also observed upon
the addition of IFN (compare lanes 3 and 7 of Figure S5A). Immu-
noprecipitation experiments further demonstrated that a lysine in
the first ten aa of the protein was required for the interaction of
YFV NS5 and STAT2 as well as the association of YFV NS5
with ubiquitin (Figure 5A).
Our results suggested direct ubiquitination of YFV NS5 K6,
although K6 could also be required for NS5 to associate with un-
anchored polyubiquitin chains or an ubiquitinated protein. When
immunoprecipitated YFV NS5 was washed in a high salt buffer,
to disrupt NS5/STAT2 interaction, a reduction in STAT2 binding
was evident but there was no change in ubiquitin binding to NS5
(Figure 5B). The strength of the association between ubiquitin
and NS5 suggested covalent linkage of ubiquitin to NS5. We
next assessed the effect of a deubiquitinating enzyme, OTUassaying for luciferase activities. Fold induction of f-luc activity was normalized to
experiments compared to the untreated empty vector controls.
(G) 293T cells were transfected with FLAG-tagged wild-type YFV NS5 and va
stimulated with IFN-b for 45 min. Cells were lysed and immunoprecipitation was p
Statistical analyses were conducted using the unpaired t test in Prism 4 (GraphP
Cell Host & Mdomain of Crimean-Congo hemorrhagic fever virus L protein,
L(1-169; Frias-Staheli et al., 2007) on the NS5-STAT2 interaction.
Incubation of NS5 with OTU decreased the NS5-STAT2 interac-
tion (Figure 5C), confirming that ubiquitination of NS5 at K6 is
required to mediate the interaction with STAT2.
Given these results, we reasoned that covalently attaching an
ubiquitin chain to theN terminus of YFVNS5K6Rmight allow this
protein to behave like wild-type NS5. We constructed clones
with a linear four-ubiquitin chain fused to the N terminus of
wild-type or the K6R mutant. Because cellular hydrolases nor-
mally remove ubiquitin chains by cleaving the LRGG sequence
of the ubiquitin C terminus, we designed ubiquitin fusions lacking
theGGportion of this sequence between ubiquitins and between
ubiquitin and NS5 (Figure 5D). Coimmunoprecipitation assays
(Figure 5E) and reporter gene assays (Figure 5F) showed that
the YFV NS5 K6R regained the ability to bind STAT2 and inhibit
IFN-I signaling when fused to linear ubiquitin. However, binding
to STAT2 was still dependent on IFN-I treatment of cells. This
may indicate that in addition to promoting YFV NS5 ubiquitina-
tion, IFN-I signaling is required for another modification that al-
lows YFV NS5 to bind to STAT2. On the other hand, it might
also be possible that YFV NS5 K6R coupled to linear ubiquitin
is not competent for binding to STAT2, and that IFN-I treatment
results in the formation of competent polyubiquitin chains that
conjugate to the fused linear tetraubiquitin at the N terminus of
YFV NS5 K6R. In any case, the functional replacement of K6 in
YFV NS5 by linear ubiquitin clearly indicates that ubiquitination
mediates the role of K6 in promoting STAT2 binding.
Most polyubiquitinated proteins are modified through K48 or
K63 ubiquitin linkage. We examined whether the NS5-STAT2
interaction was mediated by K63- or K48-linked polyubiquitin.
Upon IFN-I treatment, wild-type and K48R but not K63R ubiqui-
tin coimmunoprecipitated with both NS5 and STAT2 (Figure 5G),
indicating that K63-linked ubiquitination of YFVNS5 is necessary
for the interaction.TRIM23 Interacts with and Promotes YFV
NS5 Ubiquitination
Because TRIM E3 ligases are important modulators of IFN
signaling pathways, (McNab et al., 2011; Uchil et al., 2013; Ver-
steeg et al., 2013), and IFN-I treatment increased ubiquitination
of YFV NS5, we screened a panel of TRIM proteins from the
different TRIM family subgroups (groups I–IX) and examined their
ability to increase ubiquitination of YFVNS5. Of the TRIMs exam-
ined, expression of TRIM23 was observed to increase ubiquiti-
nation of NS5 in IFN-I-stimulated cells (data not shown). We
examined the cellular distribution of TRIM23 with wild-type or
K6R NS5 using confocal immunofluorescence. Overexpressed
TRIM23 localized in punctate perinuclear patterns, while overex-
pression of NS5 resulted in a diffuse pattern predominantly in the
nucleus. However, coexpression of TRIM23 and YFV NS5 re-
sulted in relocalization of NS5 to the punctate dot-like structuresR-luc activity. The bars represent the mean fold induction of three independent
rious HA-tagged ubiquitin mutants. At 24 hr, cells were mock stimulated or
erformed against the HA epitope followed byWBwith the indicated antibodies.
ad Software). ns, no significance, where p > 0.05; ***p < 0.0001.
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Figure 6. TRIM23 Ubiquitinates YFV NS5
(A) Confocal microscopy images showing subcellular localization of the indicated proteins in HeLa cells before or after treatment with IFN-b for 30 min.
(B) 293T cells were transfected with YFV NS5. At 24 hr, cells were mock stimulated or stimulated with IFN-b then lysed followed by immunoprecipitation. Western
blot analysis (WB) was done with the indicated antibodies.
(C) Ubiquitination assay conducted in 293T cells with increasing amounts of TRIM23. Cells were transfected with FLAG-tagged wild-type YFV NS5 or YFV NS5
K6R with increasing amounts of HA-tagged TRIM23. Lysis and immunoprecipitation against the FLAG epitope was followed by western blot analysis with the
indicated antibodies.
(D) siRNA-expressing A549 cells were infected with YFV-17DWT at an moi of 10. At 8 hpi, the cells were mock-treated or treated with 100 U/ml IFN-b. Virus was
harvested at 24 hr and viral RNA, TRIM23 and MxA RNA quantified by qPCR. Viral titers were quantified by plaque assay on BHK-21 cells.
(E) siRNA-expressing 293T cells were transfected with empty plasmid or YFV NS5 and mock treated or treated with IFN-I for 45 min. Lysis and immunopre-
cipitation were followed byWBwith the indicated antibodies. Statistical analyses were conducted using the unpaired t test in Prism 4 (GraphPad Software, USA).
ns = no significance, where p > 0.05; *** = p < 0.0001; ** = p < 0.001.
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IFN-I Activates YFV NS5 Antagonist Functioncontaining TRIM23 (Figure 6A). NS5 did not colocalize or coim-
munoprecipitate with the other TRIMs tested (Figures S6A and
S6B). In addition, NS5 precipitated endogenous TRIM23 (Fig-
ure 6B). Association of NS5 with TRIM23 was, in contrast to
association of NS5 with STAT2, independent of IFN-I treatment
(Figure 6B). Confocal immunofluorescence analysis and coim-
munoprecipitation assays showed that TRIM23 associated
with both wild-type and K6R NS5 (Figures 6A and 6B). We also322 Cell Host & Microbe 16, 314–327, September 10, 2014 ª2014 Elshow that overexpression of TRIM23 enhances ubiquitination
of WT but not mutant NS5 (Figure 6C), and that the TRIM23
RING domain is required for its interaction with NS5 (Figure S7).
In addition, silencing of TRIM23 in IFN-competent cells resulted
in increased susceptibility of YFV-17D to IFN-I and increased in-
duction of the ISG, MxA, in YFV-infected cells (Figure 6D).
Furthermore, silencing TRIM23 reduced NS5 ubiquitination and
binding to STAT2 (Figure 6E).sevier Inc.
Figure 7. STAT1 Is Necessary for IFN-I-
Induced YFV NS5-STAT2 Interaction
(A) 293T cells were transfected with the indicated
constructs. Cells were mock stimulated or stimu-
latedwith IFN-b for 45min at 24hr posttransfection.
Cell lysates were immunoprecipitated followed
by western blot analysis with the indicated anti-
bodies.
(B) Same experiment as in (A) done in U3A cells.
Right: U3A cells were complemented with wild-
type STAT1 and the same experiment was
repeated.
(C) U3A cells were complemented with wild-type
STAT1 or mutant STAT1 Y701F and the experi-
mental procedure in (B) was repeated.
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Interaction
It was intriguing that STAT1 was not precipitated along with
STAT2 after YFVNS5 immunoprecipitation (Figure 2D). Coimmu-
noprecipitation experiments using less stringent wash condi-
tions resulted in precipitation of NS5 with both STAT2 and
STAT1 (Figure 7A). These results indicate that NS5 does not
compete with STAT1 for STAT2 binding after IFN-I signaling.
Rather, NS5 strongly interacts with STAT2 whereas binding to
STAT1 likely occurs by means of IFN-I-induced STAT1/2 dimer-
ization. Consistent with this, coimmunoprecipitation of STAT1
with DENV-2 NS5/STAT2 complexes was also induced by
IFN-I treatment.
STAT degradation by the V proteins of some paramyxoviruses
requires both STAT1 and STAT2 components, even though only
one of the STAT proteins is targeted for degradation (Horvath,
2004). To explore whether the IFN-I-dependent NS5-STAT2
interaction required STAT1, we examined the NS5-STAT2 inter-
action using U3A cells, which are STAT1-deficient (McKendryCell Host & Microbe 16, 314–327, Seet al., 1991; Mu¨ller et al., 1993). Immuno-
precipitation assays showed requirement
of STAT1 for YFV NS5 to interact with
STAT2 since it did not bind STAT2 in
STAT1-deficient cells. However, DENV-
2 NS5 bound STAT2 in STAT1-deficient
cells as previously described (Ashour
et al., 2010). Complementation of U3A
cells with a wild-type STAT1 construct
rescued the ability of YFV NS5 to interact
with STAT2 after IFN-I treatment indi-
cating that STAT1 is required for NS5-
STAT2 interaction (Figure 7B). Immuno-
blot analysis revealed that STAT2 was
phosphorylated on Y690 upon IFN-I
treatment in U3A cells, which is consis-
tent with published reports (Figure 7C;
Improta et al., 1994). However, our results
showed that YFV NS5 associated with
STAT2 in response to IFN-I treatment
when cells were reconstituted with wild-
type but not mutant (Y701F) STAT1.
Given that tyrosine phosphorylation in-duces STAT1/2 heterodimers to transform from a parallel to an
antiparallel association with respect to their C- and N-termini
(Lin et al., 2009), these results suggest that the NS5 binding
domain is only exposed when STAT2 interacts with phosphory-
lated STAT1, resulting in a different STAT2 conformation. Thus,
our results indicate that IFN-I promotes YFV NS5/STAT2 interac-
tion by inducing STAT1 tyrosine phosphorylation. However, a
modification in YFV NS5, i.e., ubiquitination is also required for
STAT2 interaction. Thismodification is enhanced in the presence
of IFN and this may explain why NS5 from untreated cells is un-
able to bind STAT2 compared to NS5 from IFN-treated cells.
DISCUSSION
The experiments described in this paper demonstrate that YFV
and its NS5 protein inhibit IFN-I signaling by binding to STAT2
and preventing ISGF3 engagement with ISREs. The results
also show that IFN-I triggers YFV NS5 binding to STAT2. This
is a unique example of a viral IFN-I signaling antagonist thatptember 10, 2014 ª2014 Elsevier Inc. 323
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is incapable of binding STAT2, but IFN-I-activated NS5 binds to
both the phosphorylated and unphosphorylated forms of STAT2,
indicating that the ability of IFN-I to promote NS5-STAT2 interac-
tion is not due to IFN-I-mediated STAT2 modification. We have
identified K63-linked polyubiquitination as one of the IFN-I acti-
vating modifications of NS5. In addition, IFN-I induced tyrosine
phosphorylation of STAT1 is also required for NS5-STAT2 inter-
action, most likely by promoting conformational changes in
STAT2 that trigger its association with ubiquitinated NS5.
YFV NS5 exhibits functional similarities to DENV-2 NS5; how-
ever, DENV-2 NS5 binds STAT2 regardless of IFN treatment and
targets it for proteasome-mediated degradation (Ashour et al.,
2009). YFV NS5, on the other hand, binds STAT2 both in the
cytoplasm and nucleus only after IFN treatment, and appears
to inactivate ISGF3 within the nucleus. Mapping studies identi-
fied the first ten residues of the YFV NS5 protein as essential
for STAT2 interaction and IFN signaling inhibition. The first ten
aa of DENV-2 NS5 are critical for mediating proteasomal degra-
dation of STAT2 although they are dispensable for STAT2 asso-
ciation (Ashour et al., 2009). Therefore, the extreme N termini
of both YFV NS5 and DENV-2 NS5 contain motifs required for
their IFN antagonist function. Remarkably, the two N-termini
initiate entirely different mechanisms that ultimately converge
on STAT2 inhibition. A glycine residue and a threonine residue
within the N terminus of DENV NS5 are required for DENV NS5
to bind UBR4 (a potential E3 ligase) and mediate STAT2 degra-
dation (Morrison et al., 2013). In contrast, other E3 ligases,
such as TRIM23, polyubiquitinate K6 of YFV NS5, and this,
together with STAT1 tyrosine phosphorylation is required for
YFV NS5/STAT2 association and inhibition of ISGF3 engage-
ment with the ISRE.
K6 of YFV NS5 is critical for NS5-STAT2 interaction and IFN-I
signaling inhibition. When a K6R mutation was placed in the
context of YFV-17D, the virus displayed an enhanced sensitivity
to the antiviral action of IFN-I, indicating that K6 is important for
viral replication in the context of an ongoing IFN-I response.
Because no replication defect was seen for the K6Rmutant virus
inmock-treated Vero cells, it appears that K6may only be impor-
tant for IFN antagonism. YFV-17D causes neurotropic and vis-
cerotropic disease in immune-compromised individuals (Barrett
et al., 2007; Biscayart et al., 2014; Breugelmans et al., 2013;
Monath et al., 2005). Decreasing the ability of YFV-17D to antag-
onize IFN-I signaling may limit the replication of this vaccine in
immunocompromised individuals, thereby decreasing the inci-
dence of vaccine-associated adverse events. An YFV vaccine
that is more attenuated than, but equally or more immunogenic
to, the current YFV-17D vaccine would be an attractive alterna-
tive for YF vaccination.
These data show that K63-linked polyubiquitination of NS5
is required for STAT2 binding and IFN-I signaling inhibition.
We have shown that a linear four-ubiquitin chain fused to the
N terminus of YFV NS5 K6R binds STAT2 upon stimulation
with IFN-I. A possible explanation for these results is that the
fused linear chain serves as a K63-linked ubiquitin chain mimic
because the structures of K63-linked and linear ubiquitin are
more similar to each other than they are to the structure of
K48-linked ubiquitin (Tse et al., 2011). However, we cannot
rule out the possibility that the four-ubiquitin chain acts as a324 Cell Host & Microbe 16, 314–327, September 10, 2014 ª2014 Elnew scaffold for additional K63 polyubiquitination, which in
turns activates NS5 binding to STAT2. It is interesting that
the only requirement in the first ten aa of NS5 to bind to
STAT2 and inhibit IFN signaling was the presence of a K,
because all these residues could be substituted by a K without
loss of function. We postulate that binding of an E3 ligase
(such as TRIM23) to YFV NS5 requires a domain outside of
the first ten residues, and this brings the required E2 protein
into close contact with the N terminus of NS5, resulting in poly-
ubiquitination irrespective of the precise K location within the N
terminus.
We have also identified TRIM23, an E3 ligase involved in innate
immune signaling (Arimoto et al., 2010; Versteeg et al., 2013),
as an YFV NS5 interacting protein. TRIM23 has been shown
to promote IFN-b production by ubiquitinating NEMO (Arimoto
et al., 2010). Taylor and colleagues recently demonstrated that
TRIM79a restricts LGTV/TBEV replication by interacting with
NS5 (Taylor et al., 2011). In contrast, we show that TRIM23 pro-
motes YFV replication by polyubiquitinating YFV NS5 at its K6
residue, a modification that is required for YFV NS5-STAT2 bind-
ing. Of note, our experiments do not rule out the possible contri-
bution of other E3 ligases in ubiquitinating YFV NS5, because
there might be redundancy in their function (Morishima et al.,
2008). Nevertheless, silencing of TRIM23 results in decreased
ability of YFV to inhibit IFN-induction of MxA and increased
sensitivity of YFV to IFN-I, supporting a prominent role of
TRIM23 in YFV-mediated inhibition of IFN signaling.
Despite the high level of amino acid conservation among flavi-
virusNS5proteins, IFNantagonistic functions appear to bemedi-
ated by different mechanisms. This would suggest that IFN
signaling inhibition evolved independently among flaviviruses,
but that the NS5 protein acquired this function in all cases. It
might be that the polyprotein-based strategy of viral protein
expression that is common to all flaviviruses results in excess
production ofNS5, because only catalytic amounts of this protein
are required for RNA synthesis, making it an ideal candidate for
acquisition of additional functions.
EXPERIMENTAL PROCEDURES
Cells and Viruses
The 293T, Vero, and HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. 2fTGH and 2fTGH deriva-
tives were kindly provided by Dr. George Stark and were described previously
(Leung et al., 1995). A previously described Newcastle disease virus express-
ingGFP (NDV-GFP) was grown in 10-day-old embryonated chicken eggs (Park
et al., 2003). High titer stocks of DENV-2 16681 were obtained by passage in
C6/36 cells (Diamond et al., 2000). High titer stocks of YFV-17D strain were ob-
tained by passage in BHK-21 cells. The YFV-17D K6R mutant virus was made
by PCR mutagenesis (primer sequences are available upon request) of a YFV-
17D cDNA clone, pACNR-YF17D, kindly provided by Dr. Charles Rice (Bre-
denbeek et al., 2003; Lindenbach and Rice, 1999). The mutant virus and
wild-type control virus were rescued by linearizing the cDNA clone with
XhoI, and using the SP6 Cap-Scribe kit (Roche) to generate RNA. mRNA
was transfected into BHK-21 cells using the Transit mRNA transfection kit (Mi-
rus Bio), and virus was harvested 3 days later.
Plasmids
All flavivirus genes were cloned in the mammalian expression vector,
pCAGGS. Primer sequences used in the generation of the constructs are
available upon request. HA-NiV V plasmid was a gift from Dr. Megan Shaw.
pCAGGS-Firefly luciferase and ISRE-54-CAT reporter plasmids were giftssevier Inc.
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from by Dr. Gijs Versteeg.
Virus Infections
Monolayers of cells were initially adsorbed with YFV-17D at the indicated mul-
tiplicity of infection (moi) for 1 hr at room temperature. Unbound virus was
removed, and cells were maintained in Dulbecco’s modified Eagle’s medium
10% fetal bovine serum at 37C. For the YFV-17DK6R versus YFV-17D growth
curves, Vero cells were incubated with virus at an moi of 10 for 1 hr at 37C.
Viral replication was measured by plaque assay on BHK-21 cells.
Transfections
Lipofectamine 2000 (Invitrogen) was used for all transfections. The 293T cells
were transfected using a 1:1 ratio of plasmid DNA to Lipofectamine 2000. Vero
cells were transfected using a 1:2 ratio. 2fTGH and 2fTGH derivatives were
transfected using a 1:3 ratio.
Antibodies and Cytokines
The following antibodies were used in this study: TRIM23monoclonal antibody
(M01; Abnova), rabbit polyclonal anti-STAT1 (BD Biosciences), anti-STAT2
and anti-YFV E (Santa Cruz Biotechnology), antiphospho-STAT1 (Tyr 701;
Cell Signaling Technology), antiphospho-STAT2 (Tyr 689; Upstate Biotech-
nology), anti-HA, anti-FLAG, anti-GFP, antitubulin and anti-actin (Sigma-
Aldrich), anti-ubiquitin (Enzo Life Sciences), anti-PKR (Abcam), anti-MDA5
(Enzo AT113), and anti-DENV-2 E (Hybridoma Facility of Icahn School of Med-
icine at Mount Sinai). Rabbit antibody against DENV-2 NS5 was generated in
our lab and previously reported (Ashour et al., 2009). Anti-YFV NS5 antibody
(YF17D NS5 C7) was kindly provided by Dr. Charles Rice (Chambers et al.,
1990b). Universal IFN-I, human IFN-b, human IFN-l, and human IFN-g (PBL
Interferon Source) were used at 1,000 U/ml unless otherwise specified.
Interferon Signaling Inhibition Assays and Antibody-Based
techniques
Reporter assay, NDVGFP assay, immunoprecipitation and immunoblot assay,
immunoflourescence, and subcellular fractionation assays are described in
the Supplemental Experimental Procedures.
Quantitative RT-PCR
Total RNA, isolated from cells using RNeasy (QIAGEN), was subjected
to DNase digestion with Turbo DNase (Ambion). Reverse transcription was
performed with a cDNA reverse transcription kit (Applied Biosystems). qPCR
was done in triplicates using SYBR green I master mix (Roche) in a Roche
LightCycler 480. Relative mRNA values were calculated using ddCt method
with 18S as an internal control and shown as fold change by normalizing to
mock-control. The primers were YFV NS5 forward: GAGCTCATTGGGAGAG
GAAG; reverse: AGGCAAGCTGTTTCCTTGAT; all other primers used were
published previously (Rajsbaum et al., 2014).
siRNA Knockdown
TRIM23 siRNA-mediated knockdown experiments are described in the
Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.chom.2014.07.015.
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